We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck KGaA’s MS Treatment Not Filed by the FDA
Merck KGaA’s MS Treatment Not Filed by the FDA
December 4, 2009
Merck KGaA has received a refuse-to-file letter from the FDA for its cladribine NDA to treat relapsing forms of multiple sclerosis (MS).